An overview of Pazopanib in metastatic renal cell carcinoma mRCC in Ministry of Health MOH Malaysia: A multicentre experience
作者: May Feng Chen Nurazzahra binti Kamarudin Sandya Sandya Malwinder Singh Sandhu
刊名: Advances in Modern Oncology Research, 2017, Vol.3 (6)
来源数据库: PiscoMed Publishing Pte. Ltd
DOI: 10.18282/amor.v3.i6.275
关键词: PazopanibMetastatic renal cell carcinomaDose
原始语种摘要: Background: Pazopanib was listed in MOH, Malaysia’s drug formulary on July 2013 for the treatment of mRCC. Two landmark trials were used to support the listing i.e. VEG105192 and COMPARZ which showed a median progression free survival (PFS) of 9.2 and 8.4 months respectively. The efficacy and tolerability of Pazopanib in patients with mRCC have been found to differ in Western and Asian populations. Due to the difference in tolerability, dose adjustment in Asian patients is required. In most MOH hospitals in Malaysia, we tend to start mRCC patients with a lower dose as most patients can’t tolerate 800 mg of Pazopanib. We aim to prognosticate and evaluate PFS in patients with mRCC treated in MOH, Malaysia. We also aim to correlate PFS of patients on different doses of Pazopanib....
全文获取路径: PiscoMed Publishing  (合作)
分享到:

×
关键词翻译
关键词翻译
  • Malaysia 马来西亚
  • Ministry 
  • renal 肾的
  • carcinoma 癌症
  • start 起动
  • adjustment 
  • variable 变量
  • PFS Pinnacle Financial System
  • listed 坏布边
  • experience 体验